CRIS Current Research Information System

PILERI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.759
EU - Europa 12.804
AS - Asia 6.745
AF - Africa 732
SA - Sud America 38
Continente sconosciuto - Info sul continente non disponibili 22
OC - Oceania 15
Totale 39.115
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.694
GB - Regno Unito 4.098
CN - Cina 2.718
DE - Germania 1.744
SE - Svezia 1.588
SG - Singapore 1.568
IT - Italia 1.423
VN - Vietnam 1.306
UA - Ucraina 1.008
RU - Federazione Russa 862
IN - India 789
FR - Francia 550
IE - Irlanda 492
ZA - Sudafrica 347
EE - Estonia 300
CH - Svizzera 223
TG - Togo 137
CI - Costa d'Avorio 118
FI - Finlandia 97
SC - Seychelles 73
HR - Croazia 71
JO - Giordania 69
BG - Bulgaria 62
BE - Belgio 61
GR - Grecia 60
CA - Canada 59
IR - Iran 56
JP - Giappone 54
NL - Olanda 44
LB - Libano 43
NG - Nigeria 43
HK - Hong Kong 30
BR - Brasile 24
LU - Lussemburgo 24
AT - Austria 23
TR - Turchia 23
ID - Indonesia 18
EU - Europa 17
UZ - Uzbekistan 13
ES - Italia 12
KR - Corea 12
PL - Polonia 11
PT - Portogallo 10
RO - Romania 9
AU - Australia 8
CL - Cile 8
CZ - Repubblica Ceca 8
NZ - Nuova Zelanda 7
IQ - Iraq 6
MY - Malesia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
DK - Danimarca 5
IL - Israele 5
PE - Perù 5
PH - Filippine 5
ET - Etiopia 4
MX - Messico 4
PK - Pakistan 4
SK - Slovacchia (Repubblica Slovacca) 4
TH - Thailandia 4
TN - Tunisia 4
AL - Albania 3
BD - Bangladesh 3
HU - Ungheria 3
NO - Norvegia 3
AE - Emirati Arabi Uniti 2
CU - Cuba 2
EG - Egitto 2
KW - Kuwait 2
LT - Lituania 2
SA - Arabia Saudita 2
UG - Uganda 2
AM - Armenia 1
AR - Argentina 1
DZ - Algeria 1
GE - Georgia 1
GH - Ghana 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
MK - Macedonia 1
MT - Malta 1
NP - Nepal 1
RS - Serbia 1
TW - Taiwan 1
Totale 39.115
Salva come PNG Salva come JPEG
Città #
Southend 3.699
Fairfield 2.741
Ashburn 1.439
Woodbridge 1.379
Singapore 1.308
Chandler 1.266
Houston 1.248
Wilmington 1.201
Seattle 1.196
Cambridge 981
Princeton 882
Ann Arbor 813
Dong Ket 694
Jacksonville 638
Santa Clara 521
Dublin 492
Boardman 484
Nanjing 414
Westminster 382
Padova 374
Berlin 226
Saint Petersburg 204
Bologna 203
Jinan 196
Bern 192
Shenyang 163
Mülheim 146
Nanchang 143
San Diego 141
Lomé 137
Hebei 133
Beijing 121
New York 121
Abidjan 118
Changsha 118
Bremen 112
Milan 111
Tianjin 104
Helsinki 91
Jiaxing 87
Zhengzhou 80
Guangzhou 75
Hangzhou 70
Medford 70
Amman 69
Mahé 69
Los Angeles 67
Sofia 61
Dearborn 60
Turin 59
Ningbo 56
Norwalk 55
Taizhou 55
Brussels 54
Redwood City 54
Shanghai 52
Falls Church 50
Haikou 49
Olalla 49
San Venanzo 49
Yubileyny 49
Hyderabad 47
Tokyo 47
Taiyuan 44
Phoenix 43
Abeokuta 42
Des Moines 40
Redmond 40
Verona 40
Toronto 38
Lanzhou 33
Fuzhou 28
Rome 28
Bühl 25
Chicago 25
Frankfurt am Main 25
Fremont 24
Kunming 24
Shenzhen 23
Wuhan 23
Florence 22
Paris 22
Hong Kong 21
Moscow 20
Pune 20
Frankfurt Am Main 19
London 19
Nuremberg 19
Leawood 18
Hefei 17
Istanbul 17
Jakarta 16
Amsterdam 14
Andover 14
Dudelange 14
Lausanne 14
Falkenstein 13
Monmouth Junction 13
San Francisco 13
Shijiazhuang 13
Totale 27.248
Salva come PNG Salva come JPEG
Nome #
Biology and treatment of follicular lymphoma. 226
ANALYSIS OF THE CODING GENOME OF SPLENIC MARGINAL ZONE LYMPHOMA REVEALS MUTATIONAL ACTIVATION OF NOTCH2 AND OTHER PATHWAYS REGULATING MARGINAL ZONE DIFFERENTIATION 214
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 199
CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1 194
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target 191
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 190
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 187
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 186
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 182
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 177
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma – Authors' reply 176
The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies 172
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens 169
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 158
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 157
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 157
Clear-cell proliferation of the lung with lymphangioleiomyomatosis-like change 157
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification? 156
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 156
A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy. 154
Expression of CD52 in peripheral T-cell lymphoma. 154
Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified 154
Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. 153
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. 152
A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. 152
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 150
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 150
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 148
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 148
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 148
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 146
Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma 145
Anaplastic Large Cell Lymphoma: a critical reappraisal 144
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 144
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. 143
CD30 expression in peripheral T-cell lymphomas 143
IFI16 expression is related to selected transcription factors during B-cell differentiation 143
A case of primary MALT lymphoma of the endometrium presenting as an asymptomatic polyp. 142
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 142
CDKN1B/P27 expression in peripheral T-cell lymphoma not otherwise specified 140
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis 140
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 140
Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma 139
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 139
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 138
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 138
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. 137
BCL10 down-regulation in peripheral T-cell lymphomas. 137
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 136
B-cells and mixed cryoglobulinemia. 135
Chronic inflammation, including Autoimmunity, and Lymphomagenesis. 135
B-cell non-Hodgkin lymphomas in Uganda: an immunohistochemical appraisal on tissue microarray. 134
CDK9/Cyclin T1 expression during normal lymphoid differentiation and malignant transformation. 133
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 133
Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature 133
Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples. 132
Histopathology of B-cell chronic lymphocytic leukemia. 130
Small bowel obstruction caused by a large B-cell lymphoma in a patient with multicentric Castleman’s disease: an unusual occurrence 129
Molecular genetics of peripheral T-cell lymphomas 129
Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition 129
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. 128
Linfomi a cellule T periferiche NAS: nuovo indice prognostico. 128
The alteration of lipid metabolism in Burkitt lymphoma identifies a novel marker: adipophilin. 128
Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma. 128
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 127
Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome. 127
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma 127
Pathobiology of hodgkin lymphoma. 127
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. 126
CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies? 126
Distinctive histogenesis and immunological microenvironment based on transcriptional profiles of Follicular dendritic cell sarcomas 126
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 125
Relationship between dyskerin expression and telomerase activity in human breast cancer. 125
Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets. 125
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary - Neoplasia a cellule dendritiche plasmocitoidi blastiche: il santuario cutaneo 125
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 125
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. 125
A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. 125
Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. 124
Targeted molecular therapy in peripheral T-cell lymphomas 124
Histopathological and molecular features of persistent polyclonal B-cell lymphocytosis (PPBL) with progressive splenomegaly. 123
A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. 123
Primary effusion lymphoma associated with Human Herpes Virus-8 and Epstein Barr virus in an HIV-infected woman from Kampala, Uganda: a case report. 123
BCL10 expression in peripheral T-Cell lymphoma not otherwise specified. 123
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups 123
Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology. 123
Rare expression of KIT (CD117) in lymphomas: a tissue microarray study of 1166 cases. 122
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 122
Do bone marrow isolated tumor cells influence long-term survival of non-small cell lung cancer? 122
Primary mediastinal (Thymic) large B-cell lymphoma. 122
Familial haemophagocytic lymphohistiocytosis-related plasma cell neoplasm: a case report. 122
Aberrant somatic hypermutation in primary mediastinal large B-cell lymphoma. 122
Pitfalls in diagnosis: primary mediastinal non-seminomatous germ cell tumour with bone marrow metastasis showing melanoma-like phenotype. 121
Prognostic markers in peripheral T-cell lymphoma. 121
The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. 121
Pathobiology of anaplastic large cell lymphoma. 121
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 121
Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus 121
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 121
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 121
Totale 14.154
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.516
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.516
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.868 0 0 0 0 0 0 0 1.497 1.525 712 424 710
2020/20215.375 1.159 413 150 231 131 336 59 286 508 286 259 1.557
2021/20226.593 706 232 540 573 677 381 142 449 247 394 1.258 994
2022/20236.393 847 864 353 789 458 472 221 332 1.011 174 504 368
2023/20241.590 89 290 108 174 142 290 109 94 48 128 54 64
2024/20254.609 217 1.297 583 463 1.044 373 562 70 0 0 0 0
Totale 39.852